Related Experiment Video
Updated: Aug 9, 2025
07:45
An In Vitro Model for the Study of Cellular Pathophysiology in Globoid Cell Leukodystrophy
Published on: October 21, 2014
8.0K
Atidarsagene autotemcel for metachromatic leukodystrophy
Martina Messina1, Paul Gissen2
1Great Ormond Street Hospital for Children, London, U.K.
Drugs of Today (Barcelona, Spain : 1998)
|February 22, 2023
Summary
Gene therapy using atidarsagene autotemcel offers a new treatment for early-onset metachromatic leukodystrophy (MLD). This therapy effectively prevents disease onset and stabilizes progression in patients with MLD.
Area of Science:
- Neuroscience
- Genetics
- Metabolic Disorders
Background:
- Metachromatic leukodystrophy (MLD) is a rare, fatal autosomal recessive disorder caused by arylsulfatase A (ARSA) deficiency, leading to nervous system demyelination.
- Early-onset MLD progresses rapidly, with limited treatment options due to challenges like the blood-brain barrier hindering enzyme replacement therapy.
Approach:
- Review of preclinical and clinical studies leading to the EMA approval of atidarsagene autotemcel for early-onset MLD.
- Ex vivo gene therapy involving lentiviral vector transduction of patient-derived CD34+ hematopoietic stem/progenitor cells (HSPCs) with functional ARSA cDNA.
Key Points:
- Atidarsagene autotemcel demonstrated efficacy in preventing disease manifestations in presymptomatic patients.
- The gene therapy stabilized MLD progression in paucisymptomatic individuals.
- The treatment involves reinfusion of gene-corrected HSPCs after chemotherapy conditioning.
Conclusions:
- Atidarsagene autotemcel represents a significant therapeutic advancement for early-onset MLD.
- This gene therapy approach overcomes previous treatment limitations for MLD.
- Successful clinical application paves the way for improved outcomes in patients with this rare genetic disorder.
